Newswire (Published: Monday, February 18, 2019, Received: Tuesday, February 19, 2019, 11:56:30 PM CST)

Word Count: 489

2019 FEB 18 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Data detailed on Oncology - Prostate Cancer have been presented. According to news reporting originating in Cleveland, Ohio, by NewsRx journalists, research stated, “Few data exist in the literature regarding organ transplant recipients who are diagnosed with and treated for prostate cancer. We found excellent outcomes in transplant recipients who receive radiotherapy for prostate cancer.”

The news reporters obtained a quote from the research from Cleveland Clinic, “Few data exist in the literature regarding outcomes of men with prostate cancer (CaP) who are receiving immunosuppression from prior organ transplantation. The aim of this study was to evaluate biochemical disease-free survival, distant metastasis-free survival, overall survival, and toxicity in patients with organ transplants who were later treated with definitive radiotherapy for CaP. Our institutional CaP registry was reviewed to identify patients who had undergone an organ transplantation before CaP diagnosis. Between 1999 and 2013, a total of 28 organ transplant recipients treated with definitive radiotherapy for CaP were identified. Treatment consisted of either 1-125 low-dose-rate brachytherapy or external-beam radiotherapy. All patients were receiving immunosuppressive medications. The median age was 66 years. Median follow-up time was 30 months. Twenty-four patients (86%) were treated with brachytherapy, and 4 patients (14%) were treated with external-beam radiotherapy. Nine patients (32%) had low-risk CaP, 14 (50%) had intermediate-risk CaP, and 5 (18%) had high-risk CaP. At the time of last follow-up, 2 patients had died, 1 from metastatic CaP and 1 from other causes. The 3-year biochemical disease-free survival was 95.8%. The 3-year distant metastasis-free survival was 93.1%. The 3-year overall survival was 93.8%. One patient developed grade 3 late gastrointestinal toxicity. This represents one of the largest reported series of outcomes in patients with organ transplantation and CaP.”

According to the news reporters, the research concluded: “Organ transplant recipients treated with prostate radiotherapy have excellent 3-year outcomes.”

For more information on this research see: Outcomes in Organ Transplant Recipients With Prostate Cancer Treated With Radiotherapy. Clinical Genitourinary Cancer, 2019;17(1):e162-e166. Clinical Genitourinary Cancer can be contacted at: Cig Media Group, Lp, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier -; Clinical Genitourinary Cancer -

Our news correspondents report that additional information may be obtained by contacting R.D. Tendulkar, Cleveland Clinic, Dept. of Radiat Oncol, 9500 Euclid Ave, Desk T28, Cleveland, OH 44195, United States. Additional authors for this research include S.C. Oh, M.B. Tariq, C.A. Reddy, J.P. Ciezki and K.L. Stephans.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)


North America
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Medical Specialties and Practices
      Treatments and Therapies
            Radiation Therapy